AU2012319549B2 - Pyrazoloquinoline derivative - Google Patents
Pyrazoloquinoline derivative Download PDFInfo
- Publication number
- AU2012319549B2 AU2012319549B2 AU2012319549A AU2012319549A AU2012319549B2 AU 2012319549 B2 AU2012319549 B2 AU 2012319549B2 AU 2012319549 A AU2012319549 A AU 2012319549A AU 2012319549 A AU2012319549 A AU 2012319549A AU 2012319549 B2 AU2012319549 B2 AU 2012319549B2
- Authority
- AU
- Australia
- Prior art keywords
- group
- added
- compound
- reaction mixture
- pyrazolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161544860P | 2011-10-07 | 2011-10-07 | |
| US61/544860 | 2011-10-07 | ||
| US201161550623P | 2011-10-24 | 2011-10-24 | |
| US61/550623 | 2011-10-24 | ||
| US201161558110P | 2011-11-10 | 2011-11-10 | |
| US61/558110 | 2011-11-10 | ||
| US201161580903P | 2011-12-28 | 2011-12-28 | |
| US61/580903 | 2011-12-28 | ||
| PCT/JP2012/075748 WO2013051639A1 (ja) | 2011-10-07 | 2012-10-04 | ピラゾロキノリン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2012319549A1 AU2012319549A1 (en) | 2014-04-24 |
| AU2012319549B2 true AU2012319549B2 (en) | 2016-07-28 |
Family
ID=48043792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012319549A Active AU2012319549B2 (en) | 2011-10-07 | 2012-10-04 | Pyrazoloquinoline derivative |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US8563565B2 (he) |
| EP (1) | EP2769980B1 (he) |
| JP (1) | JP5546693B2 (he) |
| KR (1) | KR101943680B1 (he) |
| CN (1) | CN103930423B (he) |
| AR (1) | AR088235A1 (he) |
| AU (1) | AU2012319549B2 (he) |
| BR (1) | BR112014007912B1 (he) |
| CA (1) | CA2861795C (he) |
| CL (1) | CL2014000821A1 (he) |
| CO (1) | CO6910200A2 (he) |
| CY (1) | CY1117427T1 (he) |
| DK (1) | DK2769980T3 (he) |
| ES (1) | ES2568015T3 (he) |
| HK (1) | HK1199018A1 (he) |
| HR (1) | HRP20160273T1 (he) |
| HU (1) | HUE028555T2 (he) |
| IL (1) | IL231650A (he) |
| IN (1) | IN2014CN02463A (he) |
| JO (1) | JO3116B1 (he) |
| ME (1) | ME02394B (he) |
| MX (1) | MX358149B (he) |
| MY (1) | MY167698A (he) |
| PE (1) | PE20141557A1 (he) |
| PL (1) | PL2769980T3 (he) |
| RS (1) | RS54702B1 (he) |
| RU (1) | RU2605096C2 (he) |
| SG (1) | SG11201400717QA (he) |
| SI (1) | SI2769980T1 (he) |
| SM (1) | SMT201600108B (he) |
| TW (1) | TWI562993B (he) |
| WO (1) | WO2013051639A1 (he) |
| ZA (1) | ZA201402439B (he) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106905324B (zh) | 2011-10-10 | 2018-09-25 | H.隆德贝克有限公司 | 具有咪唑并吡嗪酮骨架的pde9抑制剂 |
| AU2014250391B2 (en) * | 2013-04-05 | 2017-11-02 | Eisai R&D Management Co., Ltd. | Pyridinylpyrazoloquinoline compound |
| EP2982675B1 (en) * | 2013-04-05 | 2017-08-16 | Eisai R&D Management Co., Ltd. | Salt of pyrazoloquinoline derivative, and crystal thereof |
| GB201406486D0 (en) | 2014-04-10 | 2014-05-28 | Redx Pharma Ltd | Antibacterial compounds |
| WO2016021192A1 (en) * | 2014-08-08 | 2016-02-11 | Eisai R&D Management Co., Ltd. | Process for production of (s)-(tetrahydrofuran-3-yl)hydrazine |
| AU2016289856B2 (en) | 2015-07-07 | 2020-11-26 | H. Lundbeck A/S | PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases |
| WO2017046606A1 (en) * | 2015-09-18 | 2017-03-23 | Redx Pharma Plc | Antibacterial compounds |
| CN107056690A (zh) * | 2017-03-22 | 2017-08-18 | 上海康鹏科技有限公司 | 一种6‑溴吡啶‑3‑甲醛的制备方法 |
| AU2018278422B2 (en) * | 2017-06-01 | 2022-03-17 | Eisai R&D Management Co., Ltd. | Lewy body disease therapeutic agent containing pyrazoloquinoline derivative |
| CN110603039B (zh) * | 2017-06-01 | 2023-02-28 | 卫材R&D管理有限公司 | 组合吡唑并喹啉衍生物和美金刚的痴呆治疗剂 |
| RU2019135261A (ru) * | 2017-06-01 | 2021-07-09 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Фармацевтическая композиция, содержащая ингибитор pde9 |
| JP7079777B2 (ja) * | 2017-06-01 | 2022-06-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロキノリン誘導体とドネペジルの併用による認知症治療剤 |
| CN111630042A (zh) | 2018-01-23 | 2020-09-04 | 巴斯夫欧洲公司 | 吡啶衍生物的卤化 |
| SI3801526T1 (sl) | 2018-05-25 | 2024-05-31 | Cardurion Pharmaceuticals, Inc. | Monohidratne in kristalinične oblike 6-((3s, 4s)-4-metil-1-(pirimidin-2-ilmetil)pirolidin-3-il)-3-tetrahidropiran-4- il-7h-imidazo (1.5 - a) pirazin-8-ona |
| CN112996512A (zh) * | 2018-08-31 | 2021-06-18 | 伊马拉公司 | 用于治疗镰状细胞病的pde9抑制剂 |
| US20220017499A1 (en) * | 2018-12-13 | 2022-01-20 | Intervet Inc. | Process for Preparing 1-([3R,4S)-4-Cyanotetrahydropyran-3-YL]-3-[(2-fluoro-6-Methoxy-4-Pyridyl)Amino]Pyrazole-4-Carboxamide |
| WO2020227603A1 (en) | 2019-05-09 | 2020-11-12 | The Feinstein Institutes For Medical Research | Hmgb1 antagonist |
| CN113924290A (zh) | 2019-05-09 | 2022-01-11 | 范因斯坦医学研究院 | 硫代半肼基甲酸酯及其用途 |
| CN114126619B (zh) | 2019-05-09 | 2024-03-15 | 范因斯坦医学研究院 | 用于合成肽模拟物的化合物 |
| US11883461B2 (en) | 2019-05-09 | 2024-01-30 | The Feinstein Institutes For Medical Research | HMGB1 antagonist treatment of severe sepsis |
| US11530218B2 (en) | 2020-01-20 | 2022-12-20 | Incyte Corporation | Spiro compounds as inhibitors of KRAS |
| PE20230825A1 (es) * | 2020-04-16 | 2023-05-19 | Incyte Corp | Inhibidores de kras triciclicos fusionados |
| WO2021231526A1 (en) | 2020-05-13 | 2021-11-18 | Incyte Corporation | Fused pyrimidine compounds as kras inhibitors |
| US20230303549A1 (en) | 2020-06-30 | 2023-09-28 | Bayer Aktiengesellschaft | Substituted heteroaryloxypyridines, the salts thereof and their use as herbicidal agents |
| US11999752B2 (en) | 2020-08-28 | 2024-06-04 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of KRAS |
| US11767320B2 (en) | 2020-10-02 | 2023-09-26 | Incyte Corporation | Bicyclic dione compounds as inhibitors of KRAS |
| AU2022367432A1 (en) | 2021-10-14 | 2024-05-02 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008072779A1 (ja) * | 2006-12-13 | 2008-06-19 | Aska Pharmaceutical Co., Ltd. | キノキサリン誘導体 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2426734C2 (ru) * | 2003-10-03 | 2011-08-20 | Зм Инновейтив Пропертиз Компани | Пиразолопиридины и их аналоги |
| WO2005118583A1 (en) * | 2004-05-28 | 2005-12-15 | Millennium Pharmaceuticals, Inc. | 2, 5-dihydro-pyrazolo`4, 3-c!quinolin-4-ones as chk-1 inhibitors |
| KR20080046728A (ko) * | 2005-09-15 | 2008-05-27 | 아스카 세이야쿠 가부시키가이샤 | 복소환 화합물, 그의 제조 방법 및 용도 |
| JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
| AP2524A (en) | 2007-05-11 | 2012-12-04 | Pfizer | Amino-heterocyclic compounds |
| UA105362C2 (en) * | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| RU2011140333A (ru) | 2009-03-05 | 2013-04-10 | Астеллас Фарма Инк. | Хиноксалиновое соединение |
| CA2757231A1 (en) | 2009-03-31 | 2010-10-07 | Boehringer Ingelheim International Gmbh | 1-heterocyclyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| US8880976B2 (en) | 2009-09-25 | 2014-11-04 | Stmicroelectronics, Inc. | Method and apparatus for encoding LBA information into the parity of a LDPC system |
| DK2615089T3 (en) | 2010-09-07 | 2016-06-06 | Astellas Pharma Inc | Pyrazoloquinolinforbindelser |
| JP6042060B2 (ja) * | 2011-09-26 | 2016-12-14 | サノフイ | ピラゾロキノリノン誘導体、その調製および治療上の使用 |
-
2012
- 2012-10-04 IN IN2463CHN2014 patent/IN2014CN02463A/en unknown
- 2012-10-04 PE PE2014000408A patent/PE20141557A1/es active IP Right Grant
- 2012-10-04 TW TW101136747A patent/TWI562993B/zh active
- 2012-10-04 EP EP12837953.4A patent/EP2769980B1/en active Active
- 2012-10-04 ME MEP-2016-65A patent/ME02394B/me unknown
- 2012-10-04 HU HUE12837953A patent/HUE028555T2/en unknown
- 2012-10-04 PL PL12837953T patent/PL2769980T3/pl unknown
- 2012-10-04 CN CN201280046653.2A patent/CN103930423B/zh active Active
- 2012-10-04 SG SG11201400717QA patent/SG11201400717QA/en unknown
- 2012-10-04 JP JP2013537544A patent/JP5546693B2/ja active Active
- 2012-10-04 BR BR112014007912-9A patent/BR112014007912B1/pt active IP Right Grant
- 2012-10-04 ES ES12837953.4T patent/ES2568015T3/es active Active
- 2012-10-04 AR ARP120103702A patent/AR088235A1/es active IP Right Grant
- 2012-10-04 RS RS20160232A patent/RS54702B1/en unknown
- 2012-10-04 AU AU2012319549A patent/AU2012319549B2/en active Active
- 2012-10-04 MY MYPI2014700702A patent/MY167698A/en unknown
- 2012-10-04 RU RU2014112931/04A patent/RU2605096C2/ru active
- 2012-10-04 DK DK12837953.4T patent/DK2769980T3/en active
- 2012-10-04 WO PCT/JP2012/075748 patent/WO2013051639A1/ja active Application Filing
- 2012-10-04 MX MX2014003800A patent/MX358149B/es active IP Right Grant
- 2012-10-04 JO JOP/2012/0302A patent/JO3116B1/ar active
- 2012-10-04 KR KR1020147008769A patent/KR101943680B1/ko active IP Right Grant
- 2012-10-04 CA CA2861795A patent/CA2861795C/en active Active
- 2012-10-04 US US13/644,745 patent/US8563565B2/en active Active
- 2012-10-04 SI SI201230501A patent/SI2769980T1/sl unknown
-
2013
- 2013-06-11 US US13/914,898 patent/US20130296352A1/en not_active Abandoned
-
2014
- 2014-03-19 CO CO14059034A patent/CO6910200A2/es active IP Right Grant
- 2014-03-20 IL IL231650A patent/IL231650A/he active IP Right Grant
- 2014-04-02 ZA ZA2014/02439A patent/ZA201402439B/en unknown
- 2014-04-03 CL CL2014000821A patent/CL2014000821A1/es unknown
- 2014-12-08 HK HK14112316.6A patent/HK1199018A1/zh unknown
-
2016
- 2016-03-17 HR HRP20160273TT patent/HRP20160273T1/hr unknown
- 2016-04-12 CY CY20161100302T patent/CY1117427T1/el unknown
- 2016-04-14 SM SM201600108T patent/SMT201600108B/xx unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008072779A1 (ja) * | 2006-12-13 | 2008-06-19 | Aska Pharmaceutical Co., Ltd. | キノキサリン誘導体 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012319549B2 (en) | Pyrazoloquinoline derivative | |
| US11229631B2 (en) | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors | |
| AU2014250391B2 (en) | Pyridinylpyrazoloquinoline compound | |
| WO2019074809A1 (en) | INDAZOLYL-SPIRO [2.2] PENTANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | |
| CA3162281A1 (en) | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | |
| AU2020386189B2 (en) | Adenosine receptor antagonist compounds | |
| TW201002713A (en) | Pyrrolo[2,3-d]pyrimidin-2-yl-amine derivatives as PKC-theta inhibitors | |
| NZ622594B2 (en) | Pyrazoloquinoline derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |